Roche Holding AG (RHHBY)
OTCQX OTCQX Primary Summary
RHHBY Chart
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III
RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.
Roche May Be Riding A Bit Too High, But Remains Interesting
Roche has rallied on improved sentiment around the late-stage pipeline, but near-term risk/reward is less compelling given elevated expectations and thin 2026 catalysts. The upcoming persevERA read-out for giredestrant is pivotal; strong data could unlock multi-billion-dollar peak sales, but disappointment may trigger downside as expectations have risen with lidERA results. The pipeline has produced mixed results in 2025; while giredestrant, Gazyva, and early-stage assets show promise, setbacks in other programs temper enthusiasm.
Roche Holding AG (RHHBY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Roche Holding AG ever had a stock split?
Roche Holding AG Profile
| Pharmaceuticals Industry | Healthcare Sector | Dr. Severin Schwan Ph.D. CEO | OTCQX Exchange | US7711951043 ISIN |
| US Country | 103,605 Employees | 28 Mar 2025 Last Dividend | 27 Feb 2014 Last Split | - IPO Date |
Overview
Roche Holding AG is a globally recognized healthcare company that combines its strengths in both pharmaceuticals and diagnostics. With a rich heritage dating back to 1896, the company has established a significant presence across various continents including Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. Roche is committed to improving health and well-being by providing innovative solutions and cutting-edge products in multiple therapeutic areas and diagnostics. The company's headquarters are strategically located in Basel, Switzerland, ensuring a pivotal role in the global healthcare sector.
Products and Services
Roche Holding AG offers a diverse portfolio of products and services across a broad spectrum of medical needs and diagnostic requirements. The company’s offerings can be categorized into pharmaceutical products and diagnostic solutions.
- Pharmaceutical Products: Roche is a leader in developing and marketing medicines for a wide range of diseases. Their therapeutic areas include:
- Anemia
- Blood and solid tumors
- Dermatology
- Hemophilia
- Inflammatory and autoimmune diseases
- Neurological disorders
- Ophthalmology
- Respiratory disorders
- Transplantation
- Diagnostic Solutions: In addition to pharmaceuticals, Roche provides a comprehensive range of diagnostic tools. The company's diagnostics division offers in vitro diagnostic tests for a variety of health conditions, including but not limited to:
- Cancer
- Diabetes
- Covid-19
- Hepatitis
- Human Papillomavirus (HPV)
Through its relentless pursuit of innovation and its expansive portfolio, Roche Holding AG is at the forefront of shaping the future of healthcare by addressing some of the most challenging medical needs and advancing global health.
